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ABSTRACT 
SYNTHESIS OF 4-AZIDOCOUMARINS AND THEIR USE IN 
COPPER-CATALYZED AZIDE-ALKYNE CYCLOADDITION REACTIONS 
By 
Anthony J. Nesturi 
Triazole-containing compounds have shown great biological activity 
ranging from antiviral, antibacterial, to anticancer, to name a few.  Coumarin 
derivatives have also shown interesting biological activities.  The combination of 
these bioactive compounds appears to have great promise for new and future 
medicines.  In this work, various 4-azido-coumarins were synthesized via the 
transformation of the 4-hydroxy derivatives to 4-benzotriazolyloxy coumarins    
by reaction with the peptide coupling agent 
(benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate 
(BOP), and 1,8-diazabicycloundec-7-ene (DBU) as the base, in tetrahydrofuran 
(THF) solvent.  The 4-benzotriazolyloxy coumarins were converted to the 
4-azidocoumarins by reaction with sodium azide (NaN3), and the overall process 
was simplified to a one-pot, two-step process.  The methodology reduced the need 
for additional manipulations and purifications.  Using the 4-azidocoumarins thus 
prepared, the 1,4-disubstituted-1,2,3 triazoles were synthesized via a 
copper-catalyzed alkyne-azide cycloaddition (CuAAC) reaction.  CuAAC 
reactions of the azides were optimized by screening of various copper catalysts 
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and copper tetrakis acetonitrile hexafluorophosphate ([Cu(CH3CN)4]PF6) gave the 
best results in the experiments performed.  Once the reaction conditions were 
optimized, various 4-(1,2,3-triazolyl)coumarins were synthesized in good to 
excellent yields. 
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INTRODUCTION 
The triazole moiety, as the name indicates, contains three nitrogen atoms 
in a five-membered ring.  As illustrated in Figure 1, there are two isomeric forms 
of triazoles, namely the 1,2,3 and the 1,2,4 isomers.  
 
Figure 1.  The two isomers of triazoles. 
Compounds containing these five-membered rings exhibit a wide range of 
bioactivity.1  For example, the triazole containing compound in Figure 2 has 
shown a wide spectrum of antifungal activity.2  This compound is a potent 
antifungal with the ability to competitively inhibit the enzyme activity of 
lanosterol 14α-demethylase (CYP51) in the demethylation step involved in the 
biosynthesis of ergosterol.2  Ergosterol is an important constituent of the cell 
membrane of fungi.  This antifungal property makes the mentioned compound a 
good agent to fight against the Candida species.  The antifungal effect was 
observed with a minimal concentration range of 0.0625 to 1.0000 μg/mL, with 
80% inhibition of growth of the various fungal pathogens tested.2 
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Figure 2.  An antifungal compound containing the 1,2,4-triazole motif. 
Pharmaceutical companies like AstraZeneca have used triazole 
compounds in some of their antibacterial drugs.  The utilizations of oxazolidinone 
moieties in their antibacterial compounds produced great results against 
gram-positive bacteria such as: methicillin-susceptible Staphylococcus aureus, 
penicillin-susceptible Streptococcus pneumoniae, and Haemophilius influenzae.  
The disadvantage of the oxazolidinone-derived product was its inhibitory effect 
on Monamine Oxidase-A (MAO-A) activity, which leads to severe hypertensive 
problems when the medication was used.3  To resolve this complication with the 
oxazolidinone compound Reck et al. attached a 1,2,3-triazole group, and the 
resulting compound (Figure 3) reduced the hypertensive problem produced by the 
use of the medication.  The use of the 1,2,3-triazole did not appear to affect the 
antibacterial potency.3 
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Figure 3.  An oxazolidinone antibacterial compound with a 1,2,3-triazole, which 
reduced MAO-A inhibition. 
Triazole compounds have shown beneficial results in the fight against 
diseases that have been difficult to eradicate.  Kumar et al. provided strong 
evidence that quinoline triazolyl sugar compounds attacks Mycobacterium 
tuberculosis H37Rv.4  They suggested the use of this compound as an effective 
anti-tuberculosis agent.  From the various synthesized quinoline triazolyl sugar 
compounds.  The compound in Figure 4 showed the most promise, where 
concentrations of 5 μg/mL and 25 μg/mL resulted in 76.41% and 78.37% 
reduction in relative light units in the luciferase mycobacteriophage test, 
respectively.4  In this test a plasmid is inserted into the bacterium by the phage 
virus, which contains luciferase and ampicillin resistant genes.  The ampicillin 
resistance promotes the expression of the plasmid and with it luciferase is 
synthesized by the mycobacteria, resulting in the observed light, which is 
quantified to relative light units observed from the control and compound treated 
bacterium.  The decreasing amount of light observed is correlated with the 
anti-tuberculosis activity of the quinoline triazolyl sugar compound.4 
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Figure 4.  Triazole containing compound as an anti-tuberculosis agent. 
The bioactivity benefits of the triazole moiety contribute vastly in the 
creation of new bioactive compounds, and the added advantage that other 
bioactive groups attached to it could lead to a great improvement in activity or in 
the identification of novel activity.  For example, the antiviral compound 
illustrated in Figure 5 contains a coumarin and a triazole moiety.  This compound 
performs very well through dual action as a protease and reverse transcriptase 
inhibitor. 5  The compound provides a 92% inhibition of reverse transcriptase with 
IC50 at 5.56 μM and 61% inhibition of protease activity with IC50 at 27.06 μM.5  
The combined benefit gained by coumarin and triazole makes this compound a 
very promising antiviral agent. 
 
Figure 5.  Very potent reverse transcriptase and protease inhibitor. 
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The compound discussed above (Figure 5) is related to the subject of this 
thesis, in that it contains 1,2,3-triazole linked to a coumarin moiety.  The red 
colored motif in Figure 5 is the coumarin and the blue is the 1,2,3-triazole ring.  
Coumarin is in fact a benzopyrone and the name comes from the French word for 
tonka bean “coumarou”.  Other natural sources, particularly plants such as 
Murraya siamensis6 Toddalia asiatica7and Calophyllum lanigerum,8 and 
Australian ascidians of the Didemnum species9 are a few sources of various 
coumarin compounds.  Many coumarins have fascinating and significant 
physiological as well as biological properties.  For example, the coumarins 
isolated by Ito et al. show anti-tumor activities in the Epstein-Barr 
virus-activation assay.6  This test measures the capability of the coumarin 
compounds to inhibit the ability of the Epstein-Barr virus to cause cancer in 
otherwise healthy cells. 
Chen et al. have studied the use of coumarin derivatives as anticancer 
agents.10  In this study an in vitro analysis of the compounds showed that 
7-(6-chloropyridin-2-ylthio)-4-methyl-2H-chromen-2-one was a highly potent 
compound with GI50 values ranging from 0.92 to 2.11 mM for differing cell lines 
(Figure 6.).  The compound promoted apoptosis and showed growth inhibitory 
activity in cancer cells and only weak cytotoxicity to normal cells.10 
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Figure 6.  A coumarin derivative that promoted apoptosis of lung cancer cells.
 
In a skin cancer study performed by Banerjee et al., 
4-methyl-7-hydroxycoumarin showed great ability in preventing the progression 
of skin cancer when rats were exposed to 7,12-dimethylbenz[a]anthracene 
(DMBA).11  A summary of the results from the publication of Banerjee et al., 
illustrated in a graph, is shown in Figure 7.  The data clearly show that the 
coumarin compound acted as an inhibitor of DMBA-mediated tumorigenesis.  
The authors determined that the coumarin compound prevented the cancer cells 
from entering the S phase of the DNA replication, ultimately leading to the 
reduction the tumor formation in mice.11 
 
Figure 7.  Structures of DMBA and 4-methyl-7-hydroxycoumarin. Shown to the 
right is the effect of 4-methyl-7-hydroxycoumarin on the progression of skin 
cancer in mice (graph taken from reference 11).
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Further studies on breast cancer have shown that high levels of estrogen 
synthesis are associated with the formation of tumors.  The aromatase and 
sulfatase pathways involved in the synthesis of the estrogen, are linked to the 
formation of tumors.  Studies in the chemotherapy of breast cancer have shown 
that coumarin analogs and their 7-hydroxycoumarin lower the activity of the 
sulfatase and aromatase enzymes.  This action inhibits the synthesis of estrogen, 
which has been linked to one third of breast cancer cases.12  Figure 8 shows the 
structures of the two coumarin derivatives which are known to possess this novel 
anticancer activity.12 
 
Figure 8.  Aromatase and sulfatase activity inhibiting coumarin compounds.
 
Compounds that combine the coumarin and triazole moieties have been 
reported in many publications.  Other examples 3-(1,2,3-triazolyl)coumarins and 
4-(1,2,3-triazolyl)coumarins have been previously synthesized13 and studied for 
their fluorescent properties and for their use in protein14 or DNA labeling.15  The 
labeling of protein and DNA by this metal-catalyzed cycloaddition greatly 
facilitated this process.  These reactions can be run in some part of aqueous 
solvent, making it possible to incorporate fluorophores in great yield into water 
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soluble protein without compromising their structural integrity.  The CuAAC 
method has provided various oligonucleotides that are synthesized under mild 
conditions and easily incorporated in DNA.  
 
Figure 9.  Shown to the left is a protein labeled with a fluorescent coumarin probe 
(figure taken from reference 14).  Shown to the right is thymine labeled with a 
3-(1,2,3-triazoyl)-coumarin fluorescent probe for DNA labeling (redrawn from 
reference 15). 
The 1,2,4-triazolyl coumarin shown in Figure 10 has shown good 
antibacterial and antifungal properties.16  The antibacterial properties were 
comparable to streptomycin against Bacillus subtilis, Escherichia coli, and 
Pseudomonas aeruginos.16  The compound’s antifungal activity is similar to that 
of fluconazole against fungal cultures of Aspergillus niger and Aspergillus 
flavus.16 
 
Figure 10.  Potent antibacterial triazole-coumarin conjugate. 
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A 1,2,3-triazole containing two coumarin moieties (Figure 11) presented 
significant antimycobacterial activity as against Mycobacterium tuberculosis, 
similar to streptomycin. This compound is also active against gram-positive 
bacteria, however, it was not as effective when compared to streptomycin and 
fluconazole.17 
 
Figure 11.  Antibacterial, antiviral, and antitubercular 1,4-disubstituted 
bis-coumarin triazole derivative. 
As can be seen from the foregoing, not only are triazoles and coumarins 
independently important biologically, but a combination of the two moieties also 
leads to powerful biologically valuable compounds.  Thus, we were highly 
interested in combining the biological properties of the triazolyl moiety with that 
of coumarin to generate a novel class of “triazolyl coumarins”.  We chose to 
prepare C-4 triazolyl coumarins with the general structure shown in Figure 12. 
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Figure 12.  C-4 triazolyl coumarins that were selected for synthesis. 
Two possible retrosynthetic analyses of the structural prototype depicted 
in Figure 12 are shown in Scheme 1.  In one approach (shown to the right in 
Scheme 1), a leaving group at the C-4 position of coumarin can potentially be 
displaced with a triazole.  This however, could result in the formation of N1 and 
N2 regioisomeric products.  In addition, the generality and ease of such a 
displacement with a triazole as nucleophile is unknown. 
Scheme 1.  Two possible approaches to the synthesis of C-4 triazolyl coumarins 
 
As shown to the left of Scheme 1, an alternate approach is a dipolar 
cycloaddition of a C-4 azidocoumarin derivative with an alkyne.  This appeared to 
be a methodology that could be more readily accomplished, with complete control 
over regiochemical questions.  Specifically, the coumarin would be attached to 
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the N1 of the triazole and the triazolyl substituent would be positioned at the C-4 
of the coumarin.  Further, a variety of approaches are available for the synthesis 
of terminal alkynes, e.g. Sonogashira reactions of aryl halides, Corey-Fuchs 
olefination of aldehydes followed by reaction with a strong base, and the 
Bestmann-Ohira alkynylation of aldehydes, which provide ready access to almost 
any alkyne. 
This leaves only the development of a general method for the synthesis of 
4-azidocoumarins.  A potential procedure for accomplishing this, on the basis of 
chemistry developed in our laboratories, is described later in this chapter. 
Synthesis of 1,2,3-Triazoles 
The classical method for the synthesis of the triazole ring is via a Huisgen 
ligation, which is a 2,3-dipolar cycloaddition between an alkyne and an azide. 
This reaction involves the 4π electrons of the zwitterionic azide, the dipole, and 
the 2π electrons of a neutral dipolarophile, the alkyne, resulting in a 
five-membered ring.18  The reaction occurs by the interaction of the HOMO of the 
dipole with the LUMO of the dipolarophile.  Figure 10 shows three different types 
of interactions of the dipole-dipolarophile electron densities.  The reaction types 
categorized by Huisgen are as follows. 
(a) Type 1: is a normal electron-demand type of process wherein the high-lying 
HOMO (ψ2) of the dipole interacts with the LUMO (ψB) of dipolarophile. 
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(b) Type 2: due to the similar energy gap, either the HOMO of the dipole interacts 
with the LUMO of the dipolarophile, or the LUMO of the dipole can interact 
with the HOMO of the dipolarophile. 
(c) Type 3: is the inverse-electron demand type of reaction, where the low-lying 
LUMO of the dipole (ψ3) interacts with the HOMO (ψA) of the dipolarophile. 
 
Figure 13.  HOMO and LUMO interactions between the dipole and dipolarophile 
(redrawn from ref 18). 
One major problem with the otherwise highly atom-economical Huisgen ligation 
is the propensity for the formation of regioisomeric triazoles via the 
cycloaddition.  Thus, under thermal conditions, both 1,4- and 
1,5-disubstituted-1,2,3-triazoles are formed in the Huisgen ligation (Scheme 2). 
Scheme 2.  Formation of regioisomeric products in the Huisgen ligation 
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In 2002, Meldal and colleagues,19 as well as Fokin, Sharpless, and 
colleagues,20 independently demonstrated a metal-catalyzed version of the 
Huisgen ligation, that was highly regioselective.  In the copper-catalyzed reaction, 
the use of a copper(I) catalyst largely eliminated the formation of the 
1,5-disubstituted 1,2,3-triazoles in the reaction of azides with alkynes.  The 
general term “click chemistry” was coined by Sharpless and coworkers due to the 
fact that high-energy groups (azide and alkyne) combine to form a stable, lower 
energy compound.  The copper-catalyzed reaction of azides with alkynes is now 
called CuAAC (Copper (I) catalyzed Alkyne-Azide Cycloaddition). Generally, 
the CuAAC reactions utilize an in-situ reduction of copper(II) to copper(I), or a 
copper(I) salt, and organic solvent-soluble copper salts such as [Cu(CH3CN)4]PF6 
can also be used.20 
The proposed mechanism for the CuAAC reactions postulated by Fokin 
et al.21 is shown in Figure 14.  The alkyne in the reaction reversibly coordinates 
through a weak π bond with the copper catalyst.  In the following step another 
molecule of copper catalyst forms a σ bond with the alkyne.  The azide 
coordinates with the π bound copper, and this is followed by a nucleophilic attack 
at the N3 of the azide resulting in a C–N bond.  The dinuclear copper intermediate 
proceeds rapidly to the formation of the triazolide by the oxidation of one of 
copper atoms with the stabilizing effect of the other copper atom.  Finally, 
detachment of the copper catalyst is facilitated by a proton donor, forming the 
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desired 1,4-disubstituted 1,2,3-triazole.  The catalytic cycle proceeds until the 
depletion of the reactants. 
 
Figure 14.  Catalytic cycle proposed by Fokin et al. for Cu(I) azide alkyne 
cycloaddition (ref 21). 
Synthesis of 4-Azidocoumarins 
A variety of 4-hydroxycoumarins are commercially available or are easily 
synthesized.22–24  The C-4 hydroxyl group in these compounds can be converted 
to a leaving group and then subjected to displacement with azide ion to yield 
4-azidocoumaris.  A variety of leaving groups are known at the C-4 position of 
coumarins (Scheme 3), and commonly the chloride and sulfonate derivatives of 
coumarin can be prepared.25–27 
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Scheme 3.  Coumarin derivatives with leaving groups at the C-4 position 
 
In fact, both types of reactive coumarin derivatives have been used for the 
synthesis of a variety of 4-azidocoumarin derivatives.27  However, these 
approaches require two discrete steps, namely synthesis of the reactive coumarin 
derivative and a subsequent displacement with azide ion.  Furthermore the 
halogenation procedure involves the reflux of 4-hydroxycoumarin in POCl3 and 
the formation of a modest product yield with a byproduct formation that requires 
azeotropic distillation to finally separated the products.25 
Scheme 4.  Chlorination of 4-hydroxycoumarin 
 
Research in Prof. Lakshman’s laboratories28 and from chemists at 
Weyth,29 has led to the identification of a novel method for the activation of 
amide linkages.  Specifically, Lakshman and Bae have demonstrated that reaction 
of inosine and deoxyinosine with the peptide-coupling agent 
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(1H-benzotriazol-1-yloxy)tris(dimethylamino)phosphoniumhexafluorophosphate 
(BOP) leads to the formation of O6-(benzotriazol-1-yl) nucleoside analogues 
(Scheme 5).28 
Scheme 5.  Synthesis of O6-(benzotriazol-1-yl) nucleoside derivatives 
 
Subsequently, researchers at Weyth have demonstrated similar results.29  
Importantly, in their work they have generated 4-aminoquinazoline by activation 
of 4(3H)-quinazolinone using BOP.  What should also be noted is that both 
inosine and 4-hydroxyquinazoline can be subjected to activation with BOP and 
nucleophilic displacement in a one-pot process as proposed by the authors.29 
Scheme 6.  Synthesis of 4-aminoquinazoline 
 
These benzotriazolyl intermediates are reactive towards nucleophilic 
displacement.  Notably, of relevance to the chemistry herein, Singh and 
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Lakshman have prepared azido nucleosides from the O6-(benzotriazol-1-yl) 
nucleosides in a two-step operation as shown in Scheme 7.30 
Scheme 7.  O6-(benzotriazol-1-yl) nucleosides and their use in the synthesis of 
1,2,3-triazole nucleosides 
 
We therefore reasoned that reaction of 4-hydroxycoumarin with BOP and 
a suitable base, in a suitable solvent, should yield the benzotriazolyl ether of the 
coumarin.  Whether or not this intermediate is isolable can only be determined 
only upon performing the reaction.  Secondly, on the basis of prior results, it 
should be eminently possible to synthesize 4-azidocoumarins in a two-step, 
one-pot procedure as shown in Scheme 8. 
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Scheme 8.  A potential, simple one-pot method for the synthesis of 
4-azidocoumarins 
 
Deprotonation of the hydroxycoumarin by a base should yield a 
resonance-stabilized enolate.  This species can react at the phosphorus atom of 
BOP, with loss of the benzotriazolyloxy anion, as has been demonstrated 
previously for nucleosides and pyrimidinones.28, 29  The formed benzotriazolyloxy 
anion can then displace hexamethylphosphoramide (HMPA), via an 
addition-elimination pathway, leading to the potentially isolable C-4 
benzotriazolyloxy coumarin derivative.  This species can be converted to the 
azido coumarin, via another addition-elimination reaction.  This step can either be 
performed on the isolated C-4 benzotriazolyloxy coumarin or via an in situ 
displacement, subsequent to formation of C-4 benzotriazolyloxy coumarin. 
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Once the 4-azidocoumarins become available, they can be used in CuAAC 
reactions with various alkynes, leading to C-4 triazolylcoumarins.  As stated in 
the introduction, triazoles and coumarins are both physiologically very important.  
Thus, development of synthetic methodology for combining these two structural 
motifs into a new class of 4-(4-substituted-1H-1,2,3-triazolyl)coumarins could 
result in compounds that are inherently biologically active.  We not only 
anticipate an understanding of the chemistry involved and an evaluation of the 
broad utility of the method, but we also expect to evaluate any potential 
anti-cancer and antiviral properties of the newly developed compounds (via 
collaborations) as well as mechanistic questions and other properties. 
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RESULTS AND DISCUSSION 
As described in the introduction the azidization of 4-hydroxycoumarin 
was performed by a two-step one-pot reaction.  Briefly, 4-hydroxycoumarin     
was converted to its benzotriazolyl ether by reaction with 
(benzotriazol-1-yloxy)tris(dimethylamino)phosphoniumhexafluorophosphate 
(BOP) in the presence of a base, and the newly synthesized benzotriazolyl ether 
was then converted to the azide.  The reaction and the results are summarized in 
Table 1.  For the first step of the reaction tetrahydrofuran (THF) and 
1,2-dimethoxyethane (DME) were evaluated as solvents with 
1,8-diazabicycloundec-7-ene (DBU) as the base. 
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Table 1.  The results of the various atempts in the azidization of 
4-hydroxycoumarin 
 
Entry Solvent 1 Solvent 2 Additive 
Amount 
of 
Additive 
Result, Time 
1 THF None 18-Cr-6 10 mol% 
95% Isolated yield 
Step 1 reaction time 2 hours 
Step 2 reaction time 24 hours 
2 THF None 18-Cr-6 5 mol% 
80% Isolated yield 
Step 1 reaction time 2 hours 
Step 2 reaction time 72 hours 
3 THF None Diglyme 20 mol% 
Formation of the 
benzotriazolyl ether occurred 
but azidation was not 
observed 
4 DME None None None 
Rapid formation of the 
benzotriazolyl ether occurred 
but azidation was not 
observed 
5 DME Diglyme None None 
80% Isolated yield 
Step 1 reaction time 1 hours 
Step 2 reaction time 24 hours 
6 THF EtOH None None 
90% Isolated yield 
Step 1 reaction time 2 hours 
Step 2 reaction time 24 hours 
 
The azidization step was performed after formation of the coumarin 
benzotriazoyl ether and this occurs by an addition-elimination reaction with azide 
anion as the nucleophile.  In the first attempt 10 mol% of 18-crown-6 (18-Cr-6) 
was used as shown in entry 1 in Table 1 18-Cr-6 ether is a phase-transfer catalyst, 
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which facilitates the solubility of sodium azide in organic solvents by solvation of 
the sodium cation (Na+).  However, crown ethers are relatively expensive 
compounds and in the process of purification they can contaminate the product in 
the case of an inefficient separation.  However, this reaction proceeded well and 
gave 4-azidocoumarin in 95% isolated yield.  In attempt to reduce the amount of 
crown ether, 5 mol% of 18-Cr-6 ether was used in a subsequent reaction (entry 2 
of Table 1), but this resulted in significantly slower reaction (step 2 took 
72 hours) and a product yield of 80%.  In entry 3, the same solvent system as in 
entry 2 was used, but 20 mol% of bis(2-methoxyethyl) ether was added to the 
azidation step (step 2) after the formation of the benzotriazolyl ether.  This effort 
did not prove fruitful in the azidization step.  Other attempts were directed 
towards removal of 18-Cr-6 from the azidization step via the use of other dry 
solvents.  DME and diglyme were used in an attempt to replace the crown ether 
due to their potential cation-chelating abilities.  In entry 4, use of DME provided a 
very fast reaction leading to the benzotriazolyl ether formation (1 hour for step 1).  
However, the azidization step did not occur in this solvent in a 24 hour period.  In 
entry 5 the benzotriazolyl ether formation was performed in DME solvent, the 
solvent was evaporated and diglyme was added as a solvent for the azide-forming 
step.  The step 2 of the reaction was run for 24 hours and yielded 80% of the 
isolated product.  Although diglyme was reasonable, its high boiling point and 
miscibility with organic solvent such as CH2Cl2 made it tedious to remove from 
29 
 
the reaction mixture.  For example in our workup we employed EtOAc as the 
organic solvent for extraction, and 300 mL solution containing of brine and water 
mixture at 3:7 respectively for separation.  Other difficulties could be present with 
the solubility of the substituted coumarins in EtOAc.  To remedy these difficulties 
another option was evaluated.  A web search led to the understanding that sodium 
azide is soluble in ethanol at 0.316 g/100 mL (at 16 °C).32  Thus, in entry 6 the 
formation of the benzotriazole ether was conducted in THF, then an equal volume 
of anhydrous ethanol was added followed by the addition of sodium azide into the 
reaction mixture.  With these changes, the azide forming reaction was complete 
within 24 h and gave a 90% isolated yield of 4-azidocoumarin.   
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Table 2.  Results of the azidation reactions of various coumarins.a 
 
Entry RX# R1 R2 R3 Yield 
1 74B H H H 95% 
2 84B Br H H 93% 
3 85B Cl H H 99% 
4 86B Cl H Cl 80% 
5 88B Me H H 71% 
6 89B H Me H 72% 
7 90B H MeO H 86% 
aThe benzotriazole ether step in all reactions was conducted for 2 hours at room 
temperature followed by overnight azidization.  
 
The method developed and described above for the azidization of the 
4-hydroxycoumarin (Table 1) provided us with a protocol for the formation of 
other substituted 4-azidocoumarin derivatives.  The results are summarized in 
Table 2, where the various 4-hydroxycoumarins in entries 1 to 7 have gave good 
to excellent yields of the corresponding azido derivatives, ranging from 71–99%.  
Of particular importance is the need for effective mixing during the course of 
these reactions.  Specifically, great care and consideration should be given to the 
azidization step.  Inadequate mixing gave poor yields, approximately 50%, when 
reactions were performed in screw cap vials.  The impedance to good mixing was 
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caused by the formation of an insoluble gelatinous texture of the reaction mixture 
in the azidization step.  Use of round bottom flasks provided superior results.  The 
six azidocoumarins synthesized were obtained in good yields after column 
chromatography and were then used in the azide-alkyne click reactions. 
Initially, the click reactions were performed by using the copper sulfate 
(CuSO4)/sodium ascorbate as the catalyst system originally reported by Sharpless 
and coworkers (entries 1 through 8).21  In this method CuSO4, is reduced in situ 
by sodium ascorbate.  However, the solvent system employed for entries 1–4 in 
Table 3 was CH2Cl2/H2O, the reactions were performed at room temperature and 
at 50 °C with no substantial differences observed by TLC (incomplete reactions 
with only about 50% product formation).  The solvent system in entries 5 and 6 
consisted of an ethanol–water mixture, and no product formation was observed.  
Similarly, use of t-butanol and water as the solvent system with CuSO4/sodium 
ascorbate at room temperature or at 50 oC did not result in product formation 
(entries 7 and 8).  Next, the catalytic system was changed from CuSO4/sodium 
ascorbate to copper(II) chloride (CuCl2)/sodium ascorbate as shown in entries 9 
and 10.  Reactions were conducted both at room temperature and at 50 °C, and the 
solvent system was also changed to THF/H2O.  At the elevated temperature of 
50 °C a small amount of product formation (ca 10 %) was observed by TLC.  Due 
to the observed no to low conversions with the inorganic copper-catalyzed 
reactions, the use of organic copper(I) salts were evaluated.  In entry 11, 
32 
 
effectiveness of copper(I) thiophene-2-carboxylate in CH2Cl2/CH3OH was 
evaluated 50 °C.  This reaction gave very good yield (entry 11).  Nonetheless, we 
encountered the formation of a small amount of the isomeric 1,5-triazole as 
shown by NMR in Figure 15 (small peak at 6.35 ppm). 
 
Figure 15.  NMR spectrum of copper(I) thiophene-2-carboxylate catalyzed 
reaction with products of 1,4 and traces of 1,5-(1,2,3-triazoyl)-coumarin (circled 
by the oval). 
A NOESY experiment of the 1,5-triazoyl isomer was performed and the 
data is illustrated in Figure 16.  The data shows that there is no spatial correlation 
observed between the triazoyl and the vinyl protons.  This supports the 
1,5-disubstitution pattern.  In this isomer the vinyl proton not spatially proximal to 
any other proton, especially the vinyl proton. 
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Figure 16.  NOESY spectrum in CDCl3 of 4-(5-phenyl-1H-1,2,3-triazol-1-yl)-
coumarin showing no correlation with any protons and especially the vinyl 
proton. 
Similar to the 1,5-disubstituted triazolyl coumarin, a NOESY experiment 
was conducted on the 1,4-triazoyl isomer and this is shown in Figure 17.  In this 
spectrum a clear interaction of the vinyl proton at 6.35 ppm with the triazoyl 
proton at 7.99 ppm is seen, and this is indicated by the lines. 
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Figure 17.  NOESY spectrum in CDCl3 of 4-(4-phenyl-1H-1,2,3-triazol-1-yl)-
coumarin clearly showing the correlation between the vinyl and triazolyl protons 
(conformer shown). 
The use of copper(I)-thiophene-2-carboxylate presented the possibility to 
use another organic Cu catalyst, namely tetrakis (acetonitrile) copper(I) 
hexafluorophosphate [Cu(CH3CN)4]PF6 under the same reaction conditions as 
with Cu(I) thiophene-2-carboxylate (entry 12).  A reaction with 
[Cu(CH3CN)4]PF6 resulted in a product yield of 95%, and the NMR showed 
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formation of only the 1,4-triazole regioisomer.  In entry 13, the exact reaction 
conditions used by Qian Wang et al.13 were attempted for our reaction.  The 
reactions reported by Wang et al. involve the CuAAC reactions of 
3-azidocoumarin derivatives with 5% CuSO4/10% sodium ascorbate in ethanol 
and water.13  Although they report a single example of the use of 5% CuSO4/10% 
sodium ascorbate in ethanol and water, use of these conditions for the CuAAC 
reaction of 4-azidocoumarin and 1-ethynylbenzene did not effectuate any product 
formation in our hands (as evaluated by NMR, Figure 18). 
 
Figure 18.  Crude mixture of a reaction between 4-azidocoumarin and 
1-ethynylbenzene with 5% CuSO4/10% sodium ascorbate as the catalyst in 
ethanol and water after workup showing no formation of triazole. 
In entry 14, a reaction with copper(I) iodide as catalyst in acetonitrile and 
water was performed at 50 °C, and only a low extent of product formation was 
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observed (ca 10–25%), as observed by TLC.  Due to the low conversion observed 
in entry 14, the solvent system was evaporated and replaced with CH2Cl2/CH3OH 
(entry 15).  Still, this was not effective either.  Use of copper(I) chloride in 
CH2Cl2/CH3OH again showed low conversion to product (ca 10–25%), and at 
50 °C (entry 16) no significant change was observed.  The low yielding reaction 
prompted another change of the solvent system (entry 17), and in CH3CN/CH3OH 
at 50 °C, as a light improvement was observed but conversion still remained 
(ca 20–30%), as observed by TLC. 
In summary, [Cu(CH3CN)4]PF6 proved to be the best among the catalytic 
systems tested in Table 3.  Product formation occurred in high yield and no trace 
of the isomeric 1,5-triazole was observed by NMR.  Reactions were performed in 
CH2Cl2/CH3OH, which offered good solubility for all the azidocoumarin as well 
as the catalyst.  Addition of CH3OH was used to ensure the presence of a proton 
source for the recycling of the catalyst. 
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Table 3.  Various conditions tested for the CuAAC reaction of 4-azidocoumarin 
with phenylacetylenea 
 
Entry Catalyst Solvent System Condition Yield 
1 5 mol % CuSO4 10 mol % sodium ascorbate 
DCM 0.33 mL  
H2O 0.3 mL   
rt, 24 h ~40-50% 
2 5 mol % CuSO4 10 mol % sodium ascorbate 
DCM 0.33 mL  
H2O 0.3 mL   
50 °C, 24 h ~40-50% 
3b 5 mol % CuSO4 10 mol % sodium ascorbate 
DCM 0.66 mL  
H2O 0.6 mL   
rt, 24 h ~40-50% 
4b 5 mol % CuSO4 10 mol % sodium ascorbate 
DCM 0.66 mL 
H2O 0.6 mL  
50 °C 24 h ~40-50% 
5b 12 mol % CuSO4 24 mol % sodium ascorbate 
Ethanol 0.66 mL  
H2O 0.6 mL 
rt, 24 h No Product 
6b 12 mol % CuSO4 24 mol % sodium ascorbate 
Ethanol 0.66 mL  
H2O 0.6 mL 
50 °C, 24 h No Product 
7b 12 mol % CuSO4 24 mol % sodium ascorbate 
t-Butanol 0.66 mL  
H2O 0.6 mL 
rt, 24 h No Product 
8b 12 mol % CuSO4 24 mol % sodium ascorbate 
t-Butanol 0.66 mL  
H2O 0.6 mL 
50 °C, 24 h No Product 
9b 33.5 mol % CuCl2 6.7 mol % Sodium Ascorbate 
THF 0.53 mL 
H2O 0.12 mL  
rt, 24 h No Product 
10b 33.5 mol % CuCl2 6.7 mol % sodium ascorbate 
THF 0.53 mL 
H2O 0.12 mL  
50 °C, 24 h ~10-25% 
11b 10 mol % Copper(I)-thiophene-2-carboxylate 
CH2Cl2 0.55 mL 
CH3OH 0.12 mL 
50 °C, 24 h 100% conversionc 
12b 10 mol % [(CH3CN)4Cu]PF6 
CH2Cl2 0.55 mL 
CH3OH 0.12 mL 
50 °C, 24 h 95% Yieldd 
13b 20 mol % CuCl2 20 mol % sodium ascorbate 
Ethanol 2.5 mL 
H2O 2.5 mL  
rt in dark, 24 h No producte 
14b 20 mol % CuI CH3CN 0.47 mL H2O 0.15 mL 
50 °C, 24 h ~10-25% 
15b 20 mol % CuI DCM 0.55 mL CH3OH 0.12 mL 
50 °C, 24 h ~10-25% 
16b 20 mol % CuCl DCM 0.55 mL CH3OH 0.12 mL 
50 °C, 24 h ~10-25% 
17b 20 mol % CuCl CH3CN 0.55 mL CH3OH 0.12 mL 
50 °C, 24 h ~20-30% 
aReaction were run at 0.1 mmol scale.  bReaction were run at 0.2 mmol scale.  cNot isolated yield TLC only 
andcrude mixture 1H NMR confirmed.  dIsolated yield.  eAnalysed by 1H NMR, and reaction performed based 
on literature procedure from reference 7. 
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The reaction conditions involving the use of [(CH3CN)4Cu]PF6 performed 
very well on all five alkynes that were tested in reactions with 4-azidocoumarin 
(Table 4), with yields in the range of 72–95%.  The only notable exceptions are 
shown in entries 3 and 4, involving the reactions of 1-ethynyl-4-methoxybenzene 
and 3-ethynylpyridine.  The reaction of 1-ethynyl-4-methoxybenzene was 
incomplete after 24 hours at 50 °C.  To remedy this problem the reaction was 
re-run at 80 °C for 24 hours, which resulted in a product yield of 80%.  The 
reaction of 3-ethynyl-pyridine went to completion at room temperature with a 
product yield of 95%.   
Table 4.  Alkynes used and conditions, and product yields in the CuAAC 
reactions of 4-azidocoumarina 
 
Entry Alkyne Yielda 
1 
 
95% 
2 
 
87% 
3 
 
80%b 
4 
 
95%c 
aProcedure: 0.2 mmol reaction in 0.55 mL of CH2Cl2 and 0.12 mL of CH3OH at 
50 °C for 24 h with 10 mol % of [Cu(CH3CN)4]PF6.  bReaction was performed at 
80 °C.  cReaction was performed at room temperature. 
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The reaction conditions used for the conversions of 4-azidocoumarin to 
the 4-(1,2,3)-triazolyl coumarins shown in Table 4 were then tested with the six 
substituted 4-azidocoumarins, and the results are listed in Table 5.  The overall 
reactivity of the substituted coumarin compounds remained unchanged.  As 
reported for the reaction of 4-azidocoumarin with 1-ethynyl-4-methoxybenzene, a 
similar reactivity problem was encountered in the reaction of 7-methoxycoumarin 
with 1-ethynyl-2-methyl-4-methoxybenzene (entry 4).  By TLC analysis, this 
reaction showed only a low extent of product formation.  When the reaction 
temperature was raised to 80 °C for another 24 hours, TLC showed formation of 
new uncharacterized materials indicating possible decomposition. 
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Table 5.  Various alkynes and azidocoumarin combinations in diverse CuAAC 
reactionsa 
 
Entry R R1 R2 R3 Yield 
1 
 
Br H H 67% 
2 
 
Me H H 86% 
3 
 
H Me H 89% 
4 
 
H MeO H 10-20%b 
aProcedure: 0.2 mmol reaction in 0.55 mL of CH2Cl2 and 0.12 mL of CH2Cl2 at 
50 °C over 24 h using10 mol % of [Cu(CH3CN)4]PF6.  bProduct formation is 
tracked by TLC only. 
Further optimization of at least some of these reactions                               
is necessary to improve yields.  In this aspect the use of 
tris(3-hydroxypropyltriazolylmethyl)amine and the use of 2,6-lutidine has been 
described by Sharpless et al,20 however, further experiments are needed to see if 
such additives will provide an improvement in the yields. 
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EXPERIMENTAL SECTION 
General Experimental Considerations 
Thin layer chromatography was performed on aluminum foil-backed TLC 
plates of 200 μm thickness and were visualized under short wavelength (265 nm) 
and/or long wavelength (354 nm) ultraviolet light.  Column chromatographic 
purifications were performed on 200–300 mesh silica gel.  Tetrahydrofuran (THF) 
solvent was distilled over lithium aluminum hydride (LiAlH4) then stored over 
sodium metal (Na).  It was then refluxed for at least one hour over sodium and 
distilled prior to use.  CH2Cl2 was distilled over CaCl2, and redistilled prior to use.  
Ethyl acetate (EtOAc) was distilled prior to use.  All other reagents were obtained 
from commercial sources and were used without further purification.  Proton 
NMR spectra were recorded at 500 MHz in CDCl3 and are referenced to the 
residual solvent resonance.  Carbon NMR spectra were recorded at 125 MHz in 
CDCl3 and are referenced to the residual solvent resonance.  
General procedure for the conversion of 4-hydroxycoumarin derivatives to the 
intermediateO4-(1,2,3-benzotriazolyl) derivatives, and then to the 
4-azidocoumarins. 
The conversions of various 4-hydroxycoumarin derivatives (R1=H, R2=H, 
R3=H) to the intermediate O4-(1,2,3-benzotriazolyl) derivatives and then the 
azides were conducted in a two-step, one-pot process.  As a representative 
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procedure, into a 200 mL oven-dried round bottom flask                                       
equipped with a stirring bar, was placed 4-hydroxycoumarin                         
(1.00 g, 5.09 mmol) in THF (50 mL) to give a 0.1 M solution.  
1H-Benzotriazol-1-yloxy)tris(dimethylamino)phosphoniumhexafluorophosphate 
(BOP, 2.65 g, 6.00 mmol, 1.2 equiv) was added and the mixture was stirred at 
25 °C for 10 minutes.  At this stage a white solid persists at the bottom of the 
flask.  Next DBU (0.91 mL, 6.04 mmol, 1.2 equiv) was added at which point the 
mixture became homogenous, and turned to a slight yellow solution.  The mixture 
was stirred at room temperature until completion, generally 2 h, although the 
course of the reaction was intermittently followed by TLC (SiO2/30% EtOAc in 
hexanes) until it ended.  The reaction mixture was added NaN3 (0.66 g, 
10.0 mmol, 2 equiv) followed by the addition of EtOH (200 proof, 50 mL).  The 
mixture was allowed to stir for 24 h at room temperature, and the course of 
product formation was intermittently monitored by TLC (SiO2/30% EtOAc in 
hexanes).  Upon completion of the reaction, the mixture was partitioned between 
CH2Cl2 and brine.  The organic layer was separated, dried over anhydrous 
Na2SO4, and transferred into a round bottom flask.  To this 200–300 mesh silica 
gel was added and the solvent was evaporated under reduced pressure.  The silica 
gel with the adsorbed reaction mixture was loaded onto a 200–300 mesh silica gel 
column and eluted with a mixture of EtOAc in hexanes.  Fractions containing 
pure material were combined, evaporated under reduced pressure, and vacuum 
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dried.  All azidocoumarins were synthesized in a similar manner and any 
deviations from this procedure are noted under the individual compound 
headings. 
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4-Azidocoumarin (1).  Chromatography using 10–20% EtOAc in hexanes gave 
889 mg (95% yield from a 5 mmol reaction) of compound 1 as a 
light yellow solid.  Rf (SiO2/30% EtOAc in hexanes) = 0.37.  
Melting point = 155–157 °C dec (lit.33 154–155 °C).  1H NMR 
(500 MHz, CDCl3): δ 7.72 (d, 1H, Ar-H, J = 7.8 Hz), 7.60 (t, 1H, Ar-H, 
J = 8.3 Hz), 7.35 (d, 1H, Ar-H, J = 8.3 Hz), 7.30 (t, 1H, Ar-H, J = 7.6 Hz), 6.14 
(s, 1H, =C-H).  13C NMR (125 MHz, CDCl3): δ 160.5, 153.6, 153.4, 133.2, 124.3, 
123.4, 116.9, 114.8, 100.2.  HRMS (ESI/TOF): calcd for C9H6N3O2 [M + H]+ 
188.0455, found 188.0451. 
4-Azido-6-chlorocoumarin (2).  Chromatography using gradient elution with 
10–20% EtOAc in hexanes gave 219 mg (99% yield from a 
1 mmol reaction) of compound 2 as a white solid.  
Rf (SiO2/30% EtOAc in hexanes) = 0.44.  Melting                
point = 169–171 °C dec.  1H NMR (500 MHz, CDCl3): δ 7.69 (d, 1H, Ar-H, 
J = 2.4 Hz), 7.53 (d, 1H, Ar-H, J = 8.8 Hz), 7.29 (d, 1H, Ar-H, J= 8.8 Hz), 6.16 
(s, 1H, =C-H).  13C NMR (125 MHz, CDCl3): δ 158.6, 152.1, 147.9, 133.12, 
129.6, 122.9, 121.6, 116.78, 101.3.  HRMS (ESI/TOF): calcd for C9H5ClN3O2 
[M + H]+ 222.0065, found 222.0062. 
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4-Azido-6-bromocoumarin (3).  Chromatography using gradient elution with 
15–20% EtOAc in hexanes gave 247 mg (93% yield from 
a1 mmol reaction) of compound 3 as a white solid.  
Rf (SiO2/30% EtOAc in hexanes) = 0.48.  Melting                    
point = 171–172 °C dec.  1H (500 MHz, CDCl3): δ 7.85 (d, 1H, Ar-H, J = 2.4 Hz), 
7.68 (dd, 1H, Ar-H, J = 2.2, 9.0 Hz), 7.24 (d, 1H, Ar-H, J = 8.8 Hz), 6.15 (s, 1H, 
=C-H).  13C NMR (125 MHz, CDCl3): δ 160.2, 152.7, 152.6, 136.3, 126.3, 119.0, 
117.4, 116.6, 101.2.  HRMS (ESI/TOF): calcd for C9H5BrN3O2 [M + H]+ 
265.9560, found 265.9563. 
4-Azido-6-methylcoumarin (4).  Chromatography using gradient elution with 
10–20% EtOAc in hexanes gave 143 mg (71% yield from 
a1 mmol reaction) of compound 4 as a white crystalline solid.  
Rf (SiO2/30% EtOAc in hexanes) = 0.57.  Melting      
point = 171–172 °C dec. (lit.33 140–142 °C).  1H (500 MHz, CDCl3): δ 7.44 (s, 
1H, Ar-H), 7.35 (d, 1H, Ar-H, J = 8.3 Hz), 7.18 (d, 1H, Ar-H, J = 8.3 Hz), 6.05 (s, 
1H, =C-H), 2.37 (s, 3H, CH3).  13C NMR (125 MHz, CDCl3): δ 160.7, 153.2, 
151.6, 134.1, 134.1, 122.9, 116.6, 114.4, 100.0, 20.8.  HRMS (ESI/TOF): calcd 
for C10H8N3O2 [M + H]+ 202.0611, found 202.0633. 
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4-Azido-7-methylcoumarin (5).  Chromatography using gradient elution with 
10–20% EtOAc in hexanes gave 145 mg (72% yield from a 
1 mmol reaction) of compound 5 as a white solid.  
Rf (SiO2/30% EtOAc in hexanes) = 0.46.  Melting                    
point = 160–162 °C dec. (lit.33 155–156 °C).  1H (500 MHz, CDCl3): δ 7.58 (d, 
1H, Ar-H, J = 8.3 Hz), 7.14 (s, 1H, Ar-H, J = 7.1 Hz), 7.10 (d, 1H, Ar-H, 
J = 8.3 Hz), 6.06 (s, 1H, =C-H), 2.46 (s, 3H, CH3).  13C NMR (125 MHz, CDCl3): 
δ 160.8, 153.6, 153.4, 144.6, 125.5, 122.9, 116.9, 112.3, 99.0, 21.7.  HRMS 
(ESI/TOF): calcd for C10H8N3O2 [M + H]+ 202.0611, found 202.0637. 
4-Azido-7-methoxycoumarin (6).  Chromatography using gradient elution with 
10–20% EtOAc in hexanes gave 187 mg (86% yield from a 
1 mmol reaction) of compound 6 as a light red solid.  
Rf (SiO2/30% EtOAc in hexanes) = 0.40.  Melting 
point = 173–175 °C dec. (lit.33 178–180 °C).  1H (500 MHz, CDCl3): δ 7.60 (d, 
1H, Ar-H, J = 8.8 Hz), 6.85 (dd, 1H, Ar-H, J = 2.0, 9.0 Hz), 6.82 (d, 1H, Ar-H, 
J = 2.4 Hz), 5.98 (s, 1H, =C-H), 3.88 (s, 3H, OCH3).  13C NMR (125 MHz, 
CDCl3): δ 163.9, 161.1, 155.5, 153.6, 124.4, 112.5, 108.2, 100.5, 97.0, 55.7.  
HRMS (ESI/TOF): calcd for C10H8N3O3 [M + H]+ 218.0560, found 218.0564. 
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4-Azido-6,8-dichlorocoumarin (7).  Chromatography using gradient elution with 
15–20% EtOAc in hexanes gave 205 mg (80% yield from a 
1 mmol reaction) of compound 7 as a white solid.  
Rf (SiO2/30% EtOAc in hexanes) = 0.53.  Melting             
point = 171–172 °C dec.  1H(500 MHz, CDCl3): δ 7.64 (d, 
1H, Ar-H, J = 2.5 Hz), 7.62 (d. 1H, Ar-H, J = 2.5), 6.19 (s, 1H, =C-H).  13C NMR 
(125 MHz, CDCl3): 158.9, 152.5, 148.3, 133.5, 129.9, 123.3, 121.9, 117.1, 101.6.  
HRMS (ESI/TOF): calcd for C9H4Cl2N3O2 [M + H]+ 255.9675, found 255.9675. 
 
General procedure for the azide-alkyne ligation reactions leading to the 
formation of 4-(4-substituted-1H-1,2,3-triazol-1-yl)-coumarin derivatives. 
The CuAAC reactions of various 4-azidocoumarin derivatives (R1 = H, 
R2 = H, R3 = H) as follows.  As a representative procedure, into a long (6 inch) 
screw-cap vial equipped with a stirring bar, were placed 4-azidocoumarin 
(37.4 mg, 0.2 mmol, 1 equiv) and CH2Cl2 (0.55 mL) and CH3OH (0.12 mL) and 
[Cu(CH3CN)4]PF6 (7.5 mg, 0.02 mmol, 0.10 equiv).  The mixture was stirred at 
room temperature to dissolve the reactants, then phenylacetylene (26 µL, 
0.24 mmol, 1.2 equiv) was pipetted into the reaction mixture.  The vial was 
capped and placed in a sand bath maintained at 50 °C, and left stirring overnight.  
TLC (SiO2/30% EtOAc in hexanes) showed complete reaction of the 
4-azidiocoumarin after 24 h.  The mixture was partitioned between CH2Cl2 and 
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brine.  The organic layer was separated, dried over anhydrous Na2SO4, and 
transferred to a round bottom flask.  To this 200–300 mesh silica gel was added 
and the solvent was evaporated under reduced pressure.  The silica gel with the 
adsorbed reaction mixture was loaded onto a 200–300 mesh silica gel column and 
eluted with a mixture of EtOAc in hexanes.  Fractions containing pure material 
were combined, evaporated under reduced pressure, and vacuum dried.  All 
4-triazolyl coumarins were synthesized in a similar manner and any deviations 
from this procedure are noted under the individual compound headings. 
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4-(4-Phenyl-1H-1,2,3-triazol-1-yl)-coumarin (8).  Chromatography using 
gradient elution with 25-35% EtOAc in hexanes gave 55 mg 
(95% yield from a 0.2 mmol reaction) of compound 8 as a light 
yellow solid.  Rf (SiO2/30% EtOAc in hexanes) = 0.20.  
Melting point = 178–180 °C (lit.13 166–168 °C).  1H (500 MHz, 
CDCl3): δ 8.22 (s, 1H, triazolyl-H), 7.98 (d, 1H, Ar-H, J = 8.3 Hz), 7.93 (d, 2H, 
Ar-H, J = 7.3 Hz), 7.68 (t, 1H, Ar-H, J = 7.8 Hz), 7.49 (m, 3H, Ar-H, J = 7.7 Hz), 
7.41 (m, 2H, Ar-H), 6.62 (s, 1H, =C-H).  13C NMR (125 MHz, CDCl3): δ 159.7, 
154.2, 148.5, 146.6, 133.5, 129.1, 129.1, 129.0, 126.0, 125.7, 125.0, 120.3, 117.5, 
114.3, 109.6.  HRMS (ESI/TOF): calcd for C17H12N3O2 [M + H]+ 290.0924, 
found 290.0934. 
4-(4-(p-Tolyl)-1H-1,2,3-triazol-1-yl)-coumarin (9).  Chromatography using 
gradient elution with 20-30% EtOAc in hexanes to yield 53 mg 
(87% yield from a 0.2 mmol reaction) of compound 9 as a 
white solid.  Rf  (SiO2/30% EtOAc in hexanes) = 0.28.  Melting 
point = 198–199 °C dec (lit13 181–183 °C).  1H (500 MHz, 
CDCl3): δ 8.20 (s, 1H, triazolyl-H), 8.00 (d, 1H, Ar-H, 
J = 8.3 Hz), 7.82 (d, 2H J = 7.8Hz), 7.69 (t, 1H, Ar-H, J = 7.8 Hz), 7.48 (d, 1H, 
Ar-H, J = 8.3 Hz), 7.38 (t, 1H, Ar-H, J = 7.6 Hz), 7.30 (d, 2H, Ar-H, J = 7.8 Hz), 
6.61 (s, 1H, =C-H), 2.42 (s, 3H, CH3).  13C NMR (125 MHz, CDCl3): δ 159.8, 
154.3, 148.7, 146.7, 139.2, 133.5, 129.8, 126.2, 125.9, 125.7, 125.0, 119.8, 117.5, 
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114.3, 109.5, 21.4.  HRMS (ESI/TOF): calcd for C18H14N3O2 [M + H]+ 304.1081, 
found 304.1071. 
4-(4-(4-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)-coumarin (10).  The reaction 
conditions for this compound were the same in all aspects 
except that the reaction was conducted at 80 °C.  
Chromatography using gradient elution with 30–40% 
EtOAc in hexanes to yield 51 mg (72% yield from a 
0.2 mmol reaction) of compound 10 as a white solid.  
Rf SiO2/30% EtOAc in hexanes) = 0.21.  Melting point = 196–198 °C dec (lit13 
183–185 °C).  1H (500 MHz, CDCl3): δ 8.14 (s, 1H, triazolyl-H), 8.02 (d, 1H, 
Ar-H, J = 7.8 Hz), 7.87 (d, 2H, Ar-H, J = 8.3 Hz), 7.70 (t, 1H, Ar-H, J = 7.8 Hz), 
7.49 (d, 1H, Ar-H, J = 8.3 Hz), 7.39 (t, 1H, Ar-H, J = 7.6 Hz), 7.03 (d, 2H, Ar-H, 
J = 8.8 Hz), 6.62 (s, 1H, =C-H), 3.88 (s, 3H, -OCH3).  13C NMR (125 MHz, 
CDCl3): δ 160.3, 159.8, 154.3, 148.5, 146.7, 133.5, 129.4, 127.4, 125.8, 125.0, 
121.6, 119.2, 117.6, 114.5, 109.4, 55.4.  HRMS (ESI/TOF): calcd for C18H14N3O3 
[M + H]+ 320.1030, found 320.1039. 
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4-(4-(Pyridin-3-yl)-1H-1,2,3-triazol-1-yl)-coumarin (11).  The reaction 
conditions for this compound were the same in all aspects 
except that the reaction was conducted at room temperature 
(25 °C).  Chromatography using gradient elution with 20–30% 
EtOAc in hexanes to yield 55 mg (95% yield from a 0.2 mmol 
reaction) of compound 11 as a white solid.  Rf (SiO2/30% 
EtOAc in hexanes) = 0.28.  Melting point = 145–146 °C.  1H (500 MHz, CDCl3): 
δ 8.62 (m, 2H, Ar-H and triazolyl-H), 8.26 (d, 1H, Ar-H, J = 8.3 Hz), 7.92 (dd, 
1H, Ar-H, J = 1.5, 8.3 Hz), 7.85 (t, 1H, Ar-H, J = 1.7, 7.7 Hz), 7.68 (t, 1H, Ar-H, 
J = 1.3, 7.8 Hz), 7.48 (dd, 1H, Ar-H, J = 1.0, 8.3 Hz), 7.37 (t, 1H, Ar-H, 
J = 7.7 Hz), 7.32 (ddd, 1H, Ar-H, J = 1.2, 4.9, 7.6 Hz), 6.67 (s, 1H, =C-H).  
13C NMR (125 MHz, CDCl3): δ 159.6, 154.2, 149.6, 148.9, 148.7, 146.6, 137.2, 
133.5, 125.3, 125.0, 123.6, 122.9, 120.6, 117.5, 114.2, 110.0.  HRMS (ESI/TOF): 
calcd for C16H12N4O2 [M + H]+ 291.0877, found 291.0888. 
4-(4-(Thiophen-3-yl)-1H-1,2,3-triazol-1-yl)coumarin (12).  Chromatography 
using gradient elution with 15-20% EtOAc in hexanes gave 
53 mg (89% yield from a 0.2 mmol reaction) of compound 12 
as a white solid.  Rf (SiO2/30% EtOAc in hexanes) = 0.33.  
Melting point = 185–187 °C dec.  1H (500 MHz, CDCl3): δ 8.13 
(s, 1H, triazolyl-H), 7.98 (d, 1H, Ar-H, J = 8.3 Hz), 7.87 (d, 1H, 
thienyl-H, J = 2.0 Hz), 7.70 (t, 1H Ar-H, J = 7.8 Hz), 7.55 (d, 1H, thienyl-H, 
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J = 5.1 Hz), 7.48 (m, 2H, Ar-H and thienyl-H), 7.39 (t, 1H, Ar-H, J = 7.8 Hz), 
6.62 (s, 1H, =C-H).  13C NMR (125 MHz, CDCl3): δ 159.7, 154.3, 146.7, 144.7, 
133.6, 130.1, 127.0, 125.7, 125.7, 125.1, 122.7, 119.9, 117.6, 114.4, 109.6.  
HRMS (ESI/TOF): calcd for C15H10N3O2S [M + H]+ 296.0488, found 296.0488. 
6-Bromo-4-(4-(2,4,5-trimethylphenyl)-1H-1,2,3-triazol-1-yl)coumarin (13).  
Chromatography using gradient elution with 15–25% 
EtOAc in hexanes to yield 55 mg (67% yield from a 
0.2 mmol reaction) of compound 13 as a pale yellow 
solid.  Rf (SiO2/30% EtOAc in hexanes) = 0.40.  
Melting point = 206–207 °C dec.  1H (500 MHz, 
CDCl3): δ 8.29 (d, 1H, Ar-H, J = 2.4 Hz), 8.08 (s, 1H, triazolyl-H), 7.77 (dd, 1H, 
Ar-H, J = 2.2, 8.8 Hz), 7.67 (s, 1H, Ar-H), 7.36 (d, 1H, Ar-H, J = 8.8Hz), 7.11 (s, 
1H, Ar-H), 6.63 (s, 1H, =C-H), 2.49 (s, 3H, CH3), 2.32 (s, 3H, CH3), 2.30 (s, 3H, 
CH3).  13C NMR (125 MHz, CDCl3): δ 159.1, 153.2, 148.2, 145.5, 137.7, 136.4, 
134.6, 132.8, 132.5, 130.0, 128.6, 125.4, 121.6, 119.2, 117.9, 115.8, 109.7, 20.9, 
19.5, 19.2.  HRMS (ESI/TOF): calcd for C20H17BrN3O2 [M + H]+ 410.0499, 
found 410.0485. 
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6-Methyl-4-(4-(thiophen-3-yl)-1H-1,2,3-triazol-1-yl)coumarin (14).  
Chromatography using gradient elution with 15–20% EtOAc 
in hexanes gave 55 mg (89% yield from a 0.2 mmol reaction) 
of compound 14 as a white solid.  Rf (SiO2/30% EtOAc in 
hexanes) = 0.54.  Melting point = 209–210 °C.  1H (500 
MHz, CDCl3): δ 8.11 (s, 1H, triazolyl-H), 7.87 (d, 1H, 
thienyl-H, J = 2.9 Hz), 7.73 (s, 1H, Ar-H), 7.56 (dd, 1H, thienyl-H, 
J = 1.2, 5.1 Hz), 7.46 (m, 2H, Ar-H, thienyl-H), 7.38 (d, 1H, Ar-H, J = 8.3 Hz), 
6.58 (s, 1H,  =C-H), 2.42 (s, 3H, -CH3).  13C NMR (125 MHz, CDCl3): δ 160.0, 
152.5, 146.7, 144.6, 135.7, 135.1, 134.7, 130.1, 127.2, 125.6, 125.2, 122.6, 119.9, 
117.3, 114.0, 109.6, 21.1.  HRMS (ESI/TOF): calcd for C16H12N3O2S [M + H]+ 
310.0645, found 310.0653. 
4-(4-(Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)-7-methylcoumarin (15).  
Chromatography using gradient elution with 15–20% 
EtOAc in hexanes gave 53 mg (86% yield from a 0.2 mmol 
reaction) of compound 15 as a white solid.  Rf (SiO2/30% 
EtOAc in hexanes) = 0.53.  Melting point = 208–210 °C.  
1H (500 MHz, CDCl3): δ 7.84 (m, 2H, triazolyl-H, Ar-H), 
7.23 (s, 1H, Ar-H), 7.15 (d, 1H, Ar-H, J = 8.3 Hz), 6.72 (m, 1H, =C-H), 6.45 (s, 
1H, =C-H), 2.48 (s, 3H, CH3), 2.42 (m, 2H, CH2), 2.25 (m, 2H, CH2), 1.80 (m, 
2H, CH2), 1.70 (m, 2H, CH2).  13C NMR (125 MHz, CDCl3): δ 160.2, 154.3, 
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149.9, 146.8, 145.1, 127.3, 126.1, 125.9, 125.4, 118.7, 117.5, 111.7, 107.6, 26.2, 
25.3, 22.2, 21.9, 21.7.  HRMS (ESI/TOF): calcd for C18H18N3O2 [M + H]+ 
308.1394, found 308.1397. 
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CONCLUSION 
A successfully and safe two step one pot process for the azidization of 
4-hydroxycoumarin was demonstrated in this thesis.  The process involved the 
initially transformation of 4-hydroxycoumarin to its 4-benzotriazolyloxycoumarin 
with the used of inexpensive reagents like BOP, DBU and THF.  Using this 
reaction scheme the formation of the benzotriazole ether bond was followed by 
addition elimination with sodium azide providing the azidization of the 
compounds. 
The copper catalyzed alkyne azide cycloaddition were optimized by 
screening various copper catalysts and tetrakis(acetonitrile)copper(I) 
hexafluorophosphate, which contributed to better results in this reaction.  Once 
the reaction was optimized, various 1,2,3-triazoles were synthesized                 
with good to excellent yields with the formation of solely 
1,4 substituted 1,2,3 triazoyl coumarin compounds.  As previously stated in this 
paper, other authors have worked in the synthesis of leaving groups in the 
4 position of coumarin compounds.  However, synthesis of leaving groups such as 
4-chloro and 4-sulfonate do not offer the versatility and ease of the two step one 
pot reaction that we have presented in this thesis. 
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